---
title: "Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285111709.md"
description: "Chardan Capital has maintained a Buy rating on Krystal Biotech (KRYS) with a price target of $323. Analyst Geulah Livshits, a 5-star analyst, has an average return of 12.7% and a 37.88% success rate. The overall analyst consensus for Krystal Biotech is a Strong Buy, with an average price target of $325.13."
datetime: "2026-05-04T19:45:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285111709.md)
  - [en](https://longbridge.com/en/news/285111709.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285111709.md)
---

# Chardan Capital Keeps Their Buy Rating on Krystal Biotech (KRYS)

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Krystal Biotech, with a price target of $323.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Livshits is a 5-star analyst with an average return of 12.7% and a 37.88% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Iovance Biotherapeutics, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Krystal Biotech with a $325.13 average price target.

### Related Stocks

- [KRYS.US](https://longbridge.com/en/quote/KRYS.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)
- [IOVA.US](https://longbridge.com/en/quote/IOVA.US.md)
- [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md)
- [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md)

## Related News & Research

- [Chardan Capital Sticks to Its Buy Rating for Solid Biosciences (SLDB)](https://longbridge.com/en/news/286311135.md)
- [Krystal Biotech's Medicine to Treat Wounds in Dystrophic Epidermolysis Bullosa Gets Approval in UK](https://longbridge.com/en/news/286606318.md)
- [2 Ways to Play the Big Pharma Patent Cliff](https://longbridge.com/en/news/286553222.md)
- [Oculis Holding (OCS) Gets a Buy from Chardan Capital](https://longbridge.com/en/news/286050868.md)
- [Chardan Capital Keeps Their Buy Rating on SAB Biotherapeutics (SABS)](https://longbridge.com/en/news/286193633.md)